Cargando…
Integrin Inhibitors in Prostate Cancer
Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin rece...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836076/ https://www.ncbi.nlm.nih.gov/pubmed/29415418 http://dx.doi.org/10.3390/cancers10020044 |
_version_ | 1783303908142088192 |
---|---|
author | Juan-Rivera, Maylein C. Martínez-Ferrer, Magaly |
author_facet | Juan-Rivera, Maylein C. Martínez-Ferrer, Magaly |
author_sort | Juan-Rivera, Maylein C. |
collection | PubMed |
description | Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin receptors and their corresponding ligands have different expression patterns in PCa cells. They have been identified as promising targets to inhibit pathways involved in PCa progression. Currently, several compounds have proven to target specific integrins and their subunits in PCa cells. In this article, we review the role of integrins inhibitors in PCa and their potential as therapeutic targets for PCa treatments. We have discussed the following: natural compounds, monoclonal antibodies, statins, campothecins analog, aptamers, d-aminoacid, and snake venom. Recent studies have shown that their mechanisms of action result in decrease cell migration, cell invasion, cell proliferation, and metastasis of PCa cells. |
format | Online Article Text |
id | pubmed-5836076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58360762018-03-07 Integrin Inhibitors in Prostate Cancer Juan-Rivera, Maylein C. Martínez-Ferrer, Magaly Cancers (Basel) Review Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin receptors and their corresponding ligands have different expression patterns in PCa cells. They have been identified as promising targets to inhibit pathways involved in PCa progression. Currently, several compounds have proven to target specific integrins and their subunits in PCa cells. In this article, we review the role of integrins inhibitors in PCa and their potential as therapeutic targets for PCa treatments. We have discussed the following: natural compounds, monoclonal antibodies, statins, campothecins analog, aptamers, d-aminoacid, and snake venom. Recent studies have shown that their mechanisms of action result in decrease cell migration, cell invasion, cell proliferation, and metastasis of PCa cells. MDPI 2018-02-06 /pmc/articles/PMC5836076/ /pubmed/29415418 http://dx.doi.org/10.3390/cancers10020044 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Juan-Rivera, Maylein C. Martínez-Ferrer, Magaly Integrin Inhibitors in Prostate Cancer |
title | Integrin Inhibitors in Prostate Cancer |
title_full | Integrin Inhibitors in Prostate Cancer |
title_fullStr | Integrin Inhibitors in Prostate Cancer |
title_full_unstemmed | Integrin Inhibitors in Prostate Cancer |
title_short | Integrin Inhibitors in Prostate Cancer |
title_sort | integrin inhibitors in prostate cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836076/ https://www.ncbi.nlm.nih.gov/pubmed/29415418 http://dx.doi.org/10.3390/cancers10020044 |
work_keys_str_mv | AT juanriveramayleinc integrininhibitorsinprostatecancer AT martinezferrermagaly integrininhibitorsinprostatecancer |